R Squared’s Biogen BIIB Stock Holding History

R Squared’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,760	Closed	-$378K	–	478
2025 Q1	$378K	Buy	2,760 +1,970	+249%	+$282K	0.4%	83
2024 Q4	$121K	Buy	+790	New	+$133K	0.12%	225

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's BIIB Position: Q2 2025 in Review

R Squared sold out of Biogen (BIIB) in Q2 2025, closing a stake of 2,760 shares — an estimated $378K sold.

R Squared first reported a position in BIIB in Q4 2024 and held it in 2 quarters. The position peaked at $378K in Q1 2025. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

R Squared reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
R Squared sold 2,760 Biogen shares in Q2 2025, an estimated $378K.
R Squared first reported a position in Biogen in Q4 2024 and held it in 2 quarters.
R Squared's Biogen position peaked at $378K in Q1 2025.
866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on R Squared's 13F filing for Q2 2025, filed 31 Jul 2025.